Compare Novartis AG (NVS) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs SoundHound AI Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while SoundHound AI Inc trades at $6.56 (market cap $2.75B). The key difference: Novartis AG is far larger — about 105.5× SoundHound AI Inc's market cap, and Novartis AG pays a 3.17% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals.
| NVS | SOUN | |
|---|---|---|
Market Cap | $290.25B | $2.75B |
Sector | Health | Technology |
52-Week High | $168.62 | $21.40 |
52-Week Low | $113.50 | $5.90 |
Enterprise Value | $330.27B | $2.54B |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
SoundHound AI (SOUN) trades at $6.31, up 0.64% today, but remains down 37% year-to-date. The stock shows a bearish technical trend with neutral oscillators. Fundamentally, revenue grew to $168.92 million in 2025, but net losses widened to -$14.01 million. Recent news highlights its leadership in conversational AI, yet concerns over cash burn persist. Analyst consensus is bullish with a $13.00 price target, indicating significant potential upside from current levels.
Outlook: High growth potential in voice AI markets contrasts with persistent losses and negative cash flow. Investment opportunity lies in market expansion and acquisitions, but risks include execution challenges and sustained cash burn. Investors should weigh the bullish analyst targets against the company's current unprofitability and high valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
